Blockchain Registration Transaction Record

GeoVax Showcases Strong Clinical Results for Multi-Antigen COVID-19 Vaccine

GeoVax Labs presents successful clinical data on GEO-CM04S1 vaccine at World Vaccine Congress, highlighting robust immune responses in healthy and immunocompromised populations. The dual-antigen approach demonstrates durable T cell and antibody responses, positioning the vaccine as a promising solution for COVID-19 protection.

This news matters as GeoVax's GEO-CM04S1 vaccine has shown promising results in generating immune responses in both healthy and immunocompromised individuals. The data presented at the conference indicates the vaccine's potential to provide broad and lasting protection against COVID-19, addressing the needs of high-risk populations and contributing to public health preparedness.